View Filing Data

Print Document View Excel Document

DOCUMENT AND ENTITY INFORMATION - shares	9 Months Ended
DOCUMENT AND ENTITY INFORMATION - shares	Dec. 26, 2015	Jan. 23, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--04-02
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Dec. 26, 2015
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		50,847,663

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Dec. 26, 2015	Dec. 27, 2014
Income Statement [Abstract]
Net revenues	$ 233,384	$ 231,827	$ 666,490	$ 683,895
Cost of goods sold	124,529	120,166	349,799	357,842
Gross profit	108,855	111,661	316,691	326,053
Operating expenses:
Research and development	10,942	10,643	33,816	36,962
Selling, general and administrative	78,940	82,512	240,946	259,383
Impairment of goodwill and intangible assets	85,048	0	85,048	0
Contingent consideration (income) expense	(4,898)	246	(4,727)	706
Total operating expenses	170,032	93,401	355,083	297,051
Operating (loss) income	(61,177)	18,260	(38,392)	29,002
Interest and other expense, net	(2,141)	(2,308)	(6,756)	(7,496)
(Loss) income before (benefit from) provision for income taxes	(63,318)	15,952	(45,148)	21,506
(Benefit from) provision for income taxes	(3,878)	(36)	1,696	1,679
Net (loss) income	$ (59,440)	$ 15,988	$ (46,844)	$ 19,827
Net income (loss) per share - basic (in dollars per share)	$ (1.17)	$ 0.31	$ (0.92)	$ 0.38
Net income (loss) per share - diluted (in dollars per share)	$ (1.17)	$ 0.31	$ (0.92)	$ 0.38
Weighted average shares outstanding
Basic (in shares)	50,741	51,432	50,927	51,521
Diluted (in shares)	50,741	51,962	50,927	52,024
Comprehensive (loss) income	$ (62,316)	$ 8,346	$ (66,469)	$ 10,841

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 26, 2015	Mar. 28, 2015
Current assets:
Cash and cash equivalents	$ 105,167	$ 160,662
Accounts receivable, less allowance of $2,251 at December 26, 2015 and $1,749 at March 28, 2015	148,774	145,827
Inventories, net	203,863	211,077
Deferred tax asset, net	11,995	12,608
Prepaid expenses and other current assets	31,564	40,103
Total current assets	501,363	570,277
Property, plant and equipment, net	332,772	321,948
Intangible assets, less accumulated amortization of $177,424 at December 26, 2015 and $133,175 at March 28, 2015	214,809	244,588
Goodwill	266,945	334,310
Deferred tax asset, long term	5,290	3,023
Other long-term assets	15,243	11,271
Total assets	1,336,422	1,485,417
Current liabilities:
Notes payable and current maturities of long-term debt	46,293	21,522
Accounts payable	39,636	48,425
Accrued payroll and related costs	38,204	51,115
Accrued taxes	1,791	3,819
Other current liabilities	49,410	64,211
Total current liabilities	175,334	189,092
Long-term debt, net of current maturities	380,814	406,369
Long-term deferred tax liability	33,510	32,097
Other long-term liabilities	27,212	31,737
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,798,396 shares at December 26, 2015 and 51,670,969 shares at March 28, 2015	508	517
Additional paid-in capital	435,477	426,964
Retained earnings	324,916	420,365
Accumulated other comprehensive loss	(41,349)	(21,724)
Total stockholders’ equity	719,552	826,122
Total liabilities and stockholders’ equity	$ 1,336,422	$ 1,485,417

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Dec. 26, 2015	Mar. 28, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 2,251	$ 1,749
Intangible assets, amortization	$ 177,424	$ 133,175
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	50,798,396	51,670,969
Common stock, shares outstanding (in shares)	50,798,396	51,670,969

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Cash Flows from Operating Activities:
Net (loss) income	$ (46,844)	$ 19,827
Non-cash items:
Depreciation and amortization	67,721	63,891
Impairment of goodwill and intangible assets	85,048	0
Amortization of financing costs	648	797
Stock-based compensation expense	6,199	10,219
Deferred tax benefit	(7,088)	0
Loss on sale of property, plant and equipment	29	612
Unrealized (gain)/loss from hedging activities	(2,867)	1,477
Change in fair value of contingent consideration	(4,727)	706
Asset write-down	185	1,246
Change in operating assets and liabilities:
Change in accounts receivable, net	(3,608)	14,422
Change in inventories	6,268	(17,906)
Change in prepaid income taxes	997	(219)
Change in other assets and other liabilities	6,622	(18,834)
Tax benefit of exercise of stock options	0	961
Change in accounts payable and accrued expenses	(39,971)	(5,326)
Net cash provided by operating activities	68,612	71,873
Cash Flows from Investing Activities:
Capital expenditures	(73,871)	(100,530)
Proceeds from sale of property, plant and equipment	397	387
Other acquisitions and investments	3,000	0
Net cash used in investing activities	(76,474)	(100,143)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(845)	(778)
Net increase (decrease) in short-term loans	7,143	(357)
Repayment of term loan borrowings	(7,114)	(8,531)
Proceeds from employee stock purchase plan	4,340	4,763
Proceeds from exercise of stock options	10,489	7,926
Share repurchases	(60,984)	(38,701)
Net cash used in financing activities	(46,971)	(35,678)
Effect of exchange rates on cash and cash equivalents	(662)	(3,321)
Net Change in Cash and Cash Equivalents	(55,495)	(67,269)
Cash and Cash Equivalents at Beginning of Period	160,662	192,469
Cash and Cash Equivalents at End of Period	105,167	125,200
Supplemental Disclosures of Cash Flow Information:
Interest paid	6,206	6,271
Income taxes paid	5,884	10,727
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 9,259	$ 5,755

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Dec. 26, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation Our accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the nine months ended December 26, 2015 are not necessarily indicative of the results that may be expected for the full fiscal year ending April 2, 2016, or any other interim period. Operating results for the nine months ended December 26, 2015 include the correction of an understatement of the provision for income taxes in fiscal 2015, as well as the correction of an overstated liability in fiscal 2014, both of which were determined to be immaterial to all periods impacted. Absent these corrections, our net income for the nine months ended December 26, 2015 would have been $1.1 million lower than the amount included in the accompanying Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and footnotes included in our annual report on Form 10-K for the fiscal year ended March 28, 2015. We consider events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. We had no significant subsequent events. Our fiscal year ends on the Saturday closest to the last day of March. Fiscal year 2016 includes 53 weeks with each of the first three quarters having 13 weeks and the fourth quarter having 14 weeks. Fiscal year 2015 included 52 weeks with each quarter having 13 weeks. Summary of Significant Accounting Policies Revenue Recognition We offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to estimate the expected rebates reasonably, we record a liability for the maximum potential rebate or discount that could be earned. In circumstances where we provide upfront rebate payments to customers, we capitalize the rebate payments and amortize the resulting asset as a reduction of revenue using a systematic method over the life of the contract. For additional information regarding significant accounting policies, refer to our annual report on Form 10-K for the fiscal year ended March 28, 2015.

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Dec. 26, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Standards Implemented In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. ASU No. 2014-08 limits the requirement to report discontinued operations to disposals of components of an entity that represent strategic shifts that have (or will have) a major effect on an entity’s operations and financial results. The amendments also require expanded disclosures concerning discontinued operations and disclosures of certain financial results attributable to a disposal of a significant component of an entity that does not qualify for discontinued operations reporting. The amendments in ASU No. 2014-08 are effective prospectively for reporting periods beginning on or after December 15, 2014, with early adoption permitted. We adopted ASU No. 2014-08 beginning in the first quarter of fiscal 2016. The adoption of ASU No. 2014-08 did not impact our financial position or results of operations. Standards to be Implemented In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU No. 2014-09 stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU No. 2014-09 will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within those reporting periods. Early adoption is permitted for annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The impact of adopting ASU No. 2014-09 on our financial position and results of operations is being assessed by management. In June 2014, the FASB issued ASU No. 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU No. 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC 718, Compensation—Stock Compensation, as it relates to such awards. ASU No. 2014-12 is effective in our first quarter of fiscal 2017 with early adoption permitted using either of two methods: (i) prospective to all awards granted or modified after the effective date; or (ii) retrospective to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter, with the cumulative effect of applying ASU No. 2014-12 as an adjustment to the opening retained earnings balance as of the beginning of the earliest annual period presented in the financial statements. Management does not believe that the adoption of ASU No. 2014-12 will have a material effect on our financial position or results of operations. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU No. 2014-15 defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for all entities in the first annual period ending after December 15, 2016; however, early adoption is permitted. Management does not believe that the adoption of ASU No. 2014-15 will have a material effect on our financial position or results of operations. In January 2015, the FASB issued ASU No. 2015-01, Income Statement-Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. ASU No. 2015-01 eliminates from GAAP the concept of extraordinary items. An entity will no longer be required to (1) segregate an extraordinary item from the results of ordinary operations; (2) separately present an extraordinary item on its income statement, net of tax, after income from continuing operations; and (3) disclose income taxes and earnings-per-share data applicable to an extraordinary item. ASU No. 2015-01 will be effective for fiscal years beginning after December 15, 2015. An entity may apply the amendments prospectively or retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. Management does not believe that the adoption of ASU No. 2015-01 will have a material effect on our financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. ASU No. 2015-02 amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. ASU No. 2015-02 is effective for annual periods ending after December 15, 2015, and for annual periods and interim periods thereafter with early adoption permitted. Management does not believe that the adoption of ASU No. 2015-02 will have a material effect on our financial position or results of operations. In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. ASU No. 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance simplifies the presentation of debt issuance costs but does not address presentation or subsequent measurement of debt issue costs related to line of credit arrangements. In August 2015, the FASB issued ASU No. 2015-15, Interest—Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements. ASU No. 2015-15 indicates that the SEC staff would not object to an entity deferring and presenting debt issuance costs related to line of credit arrangements as an asset and subsequently amortizing the deferred debt issuance costs over the term of the line of credit arrangement, regardless of whether there are any outstanding borrowings on the line of credit arrangement. ASU No. 2015-03 is effective for annual periods beginning after December 15, 2015, and interim periods within those annual periods. Early adoption is permitted. Management does not believe that the adoption of ASU No. 2015-03 will have a material effect on our financial position or results of operations. In April 2015, the FASB issued ASU No. 2015-04, Compensation—Retirement Benefits (Topic 715): Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets. ASU No. 2015-04 provides a practical expedient, for an entity with a fiscal year-end that does not coincide with a month-end, that permits the entity to measure defined benefit plan assets and obligations using the month-end that is closest to the entity's fiscal year-end and apply that practical expedient consistently from year to year. ASU No. 2015-04 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early application is permitted. Management does not believe that the adoption of ASU No. 2015-04 will have a material effect on our financial position or results of operations. In April 2015, the FASB issued ASU No. 2015-05, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement. ASU No. 2015-05 will help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement. ASU No. 2015-05 is effective for interim and annual periods beginning after December 15, 2015 with early adoption permitted. Management does not believe that the adoption of ASU No. 2015-05 will have a material effect on our financial position or results of operations. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU No. 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value. ASU No. 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. ASU No. 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. Management does not believe that the adoption of ASU No. 2015-11 will have a material effect on our financial position or results of operations. In August 2015, the FASB issued ASU No. 2015-12, Plan Accounting: Defined Benefit Pension Plans (Topic 960), Defined Contribution Pension Plans (Topic 962), Health and Welfare Benefit Plans (Topic 965): (Part I) Fully Benefit-Responsive Investment Contracts, (Part II) Plan Investment Disclosures, (Part III) Measurement Date Practical Expedient. Part I of ASU No. 2015-12 designates contract value as the only required measure for fully benefit-responsive investment contracts. Part II simplifies the investment disclosure requirements under Topics 820, 960, 962, and 965 for employee benefits plans and Part III provides a measurement date practical expedient for fiscal periods that do not coincide with a month-end date. ASU No. 2015-12 is effective for fiscal years beginning after December 15, 2015 with early adoption permitted. Management does not believe that the adoption of ASU No. 2015-12 will have a material effect on our financial position or results of operations. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. ASU No. 2015-17 simplifies the presentation of deferred taxes on a classified balance sheet. Currently under GAAP, deferred income tax assets and liabilities are separated into current and non-current amounts in the balance sheet. ASU No. 2015-17 requires that all deferred tax assets and liabilities be classified as non-current in the balance sheet. ASU No. 2015-17 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods, with early adoption permitted. Management believes the adoption of ASU No. 2015-17 will have an impact on our financial statement presentation, but will not have a material effect on our financial position or results of operations.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

+ Details

EARNINGS PER SHARE ("EPS")

9 Months Ended

Dec. 26, 2015

Earnings Per Share [Abstract]

EARNINGS PER SHARE (EPS)

EARNINGS PER SHARE (“EPS”)

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.



	Three Months Ended
(In thousands, except per share amounts)	December 26, 2015			December 27, 2014
Basic EPS
Net (loss) income	$	(59,440	)	$	15,988
Weighted average shares	50,741			51,432
Basic (loss) income per share	$	(1.17	)	$	0.31
Diluted EPS
Net (loss) income	$	(59,440	)	$	15,988
Basic weighted average shares	50,741			51,432
Net effect of common stock equivalents	—			530
Diluted weighted average shares	50,741			51,962
Diluted (loss) income per share	$	(1.17	)	$	0.31



	Nine Months Ended
(In thousands, except per share amounts)	December 26, 2015			December 27, 2014
Basic EPS
Net (loss) income	$	(46,844	)	$	19,827
Weighted average shares	50,927			51,521
Basic (loss) income per share	$	(0.92	)	$	0.38
Diluted EPS
Net (loss) income	$	(46,844	)	$	19,827
Basic weighted average shares	50,927			51,521
Net effect of common stock equivalents	—			503
Diluted weighted average shares	50,927			52,024
Diluted (loss) income per share	$	(0.92	)	$	0.38

Basic earnings per share is calculated using our weighted-average outstanding common shares. Diluted earnings per share is calculated using our weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method. For the three and nine months ended December 26, 2015, we recognized a net loss; therefore we excluded the impact of outstanding stock awards from the diluted loss per share calculation as their inclusion would have an anti-dilutive effect. Weighted average shares outstanding, assuming dilution, excludes the impact of 1.7 million and 1.6 million anti-dilutive shares for the three and nine months ended December 27, 2014, respectively.

STOCK-BASED COMPENSATION

9 Months Ended

Dec. 26, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Total stock-based compensation expense of $6.2 million and $10.2 million was recognized for the nine months ended December 26, 2015 and December 27, 2014, respectively. There was no related income tax benefit recognized for the nine months ended December 26, 2015 and the related income tax benefit recognized for the nine months ended December 27, 2014 was $3.3 million.

The weighted average fair value for our options granted was $7.41 and $7.89 per share for the nine months ended December 26, 2015 and December 27, 2014, respectively. The assumptions utilized for estimating the fair value of option grants during the periods presented are as follows:



	Nine Months Ended
	December 26, 2015		December 27, 2014
Stock Options Black-Scholes assumptions (weighted average):
Volatility	22.82	%	22.45	%
Expected life (years)	4.9		4.9
Risk-free interest rate	1.40	%	1.75	%
Dividend yield	—	%	—	%

As of December 26, 2015, there was $18.2 million of total unrecognized compensation cost related to non-vested equity based compensation, including stock options, restricted stock units, market stock units and performance share units. This cost is expected to be recognized over a weighted average period of 2.9 years.

During the nine months ended December 26, 2015 and December 27, 2014, there were 145,334 and 183,808 shares, respectively, purchased under the Employee Stock Purchase Plan at an average price of $29.87 and $25.92 per share, respectively.

PRODUCT WARRANTIES

9 Months Ended

Dec. 26, 2015

Product Warranties Disclosures [Abstract]

PRODUCT WARRANTIES

We generally provide warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience and periodically assess the adequacy of our warranty accrual, making adjustments as necessary.



	Nine Months Ended
(In thousands)	December 26, 2015			December 27, 2014
Warranty accrual as of the beginning of the period	$	531		$	590
Warranty provision	532			890
Warranty spending	(701		)	(941		)
Warranty accrual as of the end of the period	$	362		$	539

GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Dec. 26, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS

Goodwill Impairment Testing and Charges

Under ASC Topic 350, Intangibles - Goodwill and Other, goodwill and intangible assets determined to have indefinite useful lives are not amortized. Instead these assets are evaluated for impairment at least annually, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. We perform our annual impairment test on the first day of the fiscal fourth quarter for each of our reporting units. Our reporting units for purposes of assessing goodwill impairment are the same as our operating segments, which are organized primarily based on geography and include: North America Plasma, Americas Blood Center and Hospital, Europe, Middle East, and Africa (collectively "EMEA"), Asia-Pacific and Japan. The North America Plasma reporting unit is a separate operating segment with dedicated segment management due the size and scale of the plasma business.

During the third quarter of each fiscal year, we prepare our long term projections for net revenues, income and operating cash flows. The economic weakness in EMEA, particularly Russia, and declines in our U.S. blood center collections have negatively impacted earnings before interest, taxes, depreciation, and amortization ("EBITDA") and net revenues for our EMEA and Americas Blood Center and Hospital reporting units. Because of these market conditions and key uncertainties, including the market rate of adoption of our new products and the negative impact of intense competitive pressure on pricing and market share, we lowered our expectations in terms of the timing and amount of our future revenue, income and cash flows. As a result, we concluded in the third quarter of fiscal 2016 that indicators of potential goodwill impairment were present for the EMEA and Americas Blood Center and Hospital reporting units, therefore requiring an interim test for goodwill impairment.

In accordance with ASC Topic 350, we prepared a “Step 1” Test that compared the estimated fair value of each reporting unit to its carrying value. We utilized a discounted cash flow approach in order to value our reporting units for the Step 1 Test, which required that we forecast future cash flows of the reporting units and discount the cash flow stream based upon a weighted average cost of capital that was derived, in part, from comparable companies within similar industries. The discounted cash flow calculations also included a terminal value calculation that was based upon an expected long-term growth rate for the applicable reporting unit. We believe that our procedures for estimating discounted future cash flows, including the terminal valuation, are reasonable and consistent with market conditions at the time of estimation. We corroborated the valuations that arose from the discounted cash flow approach by performing both a market multiple valuation and by reconciling the aggregate fair value of our reporting units to our market capitalization at the time of the test.

The results of the Step 1 Test performed in the third quarter of fiscal 2016 indicated that the estimated fair value of all of our reporting units exceeded their respective carrying values, with the exception of EMEA, for which we recorded an estimated goodwill impairment charge, as discussed below. Based on this Step 1 analysis, the reporting unit that is most at risk of impairment in future periods is the Americas Blood Center and Hospital, which has an excess fair value over carrying value of approximately 25.8% and has allocated goodwill of $175.9 million as of December 26, 2015. We believe that our assumptions used to determine the fair value of the Americas Blood Center and Hospital reporting unit were reasonable. If different assumptions were to be used, particularly with respect to estimating future cash flows, or if actual operating results and cash flows of the Americas Blood Center and Hospital differ from the estimated operating results and related cash flows, there is the potential that an impairment charge could result in future periods. Additionally, changes to the discount rate or the long-term growth rate could also give rise to an impairment in future periods.

As a result of the carrying value of the EMEA reporting unit exceeding its estimated fair value, a "Step 2" Test is required for this reporting unit. The Step 2 Test measures the impairment loss by allocating the estimated fair value of the reporting unit, as determined in Step 1, to the reporting units’ assets and liabilities, with the residual amount representing the implied fair value of goodwill. To the extent the implied fair value of goodwill is less than the carrying value, an impairment loss is recognized.

The Step 2 Test under ASC Topic 350 requires us to perform a theoretical purchase price allocation for the EMEA reporting unit to determine the implied fair value of goodwill as of the evaluation date. Due to the complexity of the analysis required to complete the Step 2 Test and the timing of our determination of the Step 1 goodwill impairment, we have not yet finalized our Step 2 Test, however, we have completed a preliminary assessment of the expected impact of the Step 1 and Step 2 Tests using reasonable estimates of discounted cash flows and for the theoretical purchase price allocation. Based on this assessment, we have recorded a preliminary estimate of the goodwill impairment loss for the third quarter and first nine months ended December 26, 2015 of $66.3 million, which represents the entire goodwill balance allocated to EMEA. This charge does not impact our liquidity, cash flows from operations, future operations, or compliance with debt covenants.

The preliminary estimates of goodwill impairment loss will be finalized prior to the issuance of our Form 10-K for the year ended April 2, 2016 as part of our annual evaluation as of the first day of our fiscal fourth quarter. We believe that the preliminary estimate of goodwill impairment loss is reasonable and represents our best estimate of the goodwill impairment loss to be incurred; however, it is possible that when the year-end tests are completed we may be required to record a material adjustment to this preliminary estimate.

The following procedures are, among others, the more significant analyses that we need to complete to finalize our year end Step 2 Tests for the EMEA reporting unit:


•	Final appraisals to determine the estimated fair value of identifiable intangible assets.


•	Final analysis to determine the estimated fair value adjustment required to inventory.


•	Final deferred tax analysis.

In connection with the preliminary Step 2 Tests, we made what we considered to be reasonable estimates of each of the above items in order to determine our preliminary best estimate of the goodwill impairment loss under the theoretical purchase price allocation required for Step 2 Tests by ASC Topic 350. The completion of the final analyses described above may result in significant changes to the estimates used and therefore may have a significant impact on the final goodwill impairment loss recorded for fiscal 2016. In addition, we may identify other issues during the completion of the Step 2 Tests that may have a significant impact on the final goodwill impairment loss recorded for fiscal 2016.

The changes in the carrying amount of goodwill for fiscal 2016 and 2015 are as follows:



(In thousands)
Carrying amount as of March 29, 2014	$	336,768
Effects of change in foreign currency exchange rates	(2,458		)
Carrying amount as of March 28, 2015	$	334,310
Impairment charge	(66,305		)
Effects of change in foreign currency exchange rates	(1,060		)
Carrying amount as of December 26, 2015	$	266,945

Intangible Asset Impairment

In April 2013, we acquired a patented red cell storage solution, referred to as SOLX, from Hemerus Medical, LLC for cash consideration of $24.1 million plus an agreement to make certain future payments accounted for as contingent consideration.

During the third quarter of fiscal 2016, we received U.S. Food and Drug Administration clearance for the SOLX solution with a Haemonetics whole blood filter. Currently, the vast majority of the U.S. market utilizes a red cell filter, not a whole blood filter, for whole blood collection procedures as they seek to optimize blood component yield from each collection. To bring SOLX to market with a red cell filter requires substantial additional investment. Accordingly, we conducted a final market review prior to proceeding with this investment, which indicated customers would not pay a price for a SOLX collection kit sufficient to recover the cost to produce it, or to provide an adequate return on the additional investment. As result, we have suspended further investment in the SOLX technology and have recorded an impairment charge of $18.7 million to write down the carrying value of the SOLX intangible assets as of December 26, 2015. In addition, we reversed the $4.9 million of contingent consideration liability we had recorded, as we now do not expect to achieve the conditions that called for its payment.

The gross carrying amount of intangible assets and the related accumulated amortization, as of December 26, 2015 and March 28, 2015 is as follows:



(In thousands)	Gross Carrying Amount		Accumulated Amortization⁽¹⁾		Net		Weighted Average Useful Life
							(In years)
As of December 26, 2015
Patents	$	11,210	$	7,445	$	3,765	9
Capitalized software	52,557		9,242		43,315		6
Other developed technology	126,066		70,887		55,179		12
Customer contracts and related relationships	195,368		84,758		110,610		10
Trade names	7,032		5,092		1,940		11
Total intangibles	$	392,233	$	177,424	$	214,809	10

⁽¹⁾Includes impairment of SOLX asset, as discussed above.



(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Useful Life
							(In years)
As of March 28, 2015
Patents	$	10,473	$	7,373	$	3,100	9
Capitalized software	39,690		5,654		34,036		7
Other developed technology	124,573		46,474		78,099		12
Customer contracts and related relationships	195,985		70,440		125,545		10
Trade names	7,042		3,234		3,808		11
Total intangibles	$	377,763	$	133,175	$	244,588	10

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are 2 to 19 years. The changes to the net carrying value of our intangible assets from March 28, 2015 to December 26, 2015 reflect the impact of the SOLX impairment discussed above and amortization expense, partially offset by the investment in capitalized software and other less significant intangible assets.

Aggregate amortization expense for amortized intangible assets, excluding the impact of the SOLX impairment, for the nine months ended December 26, 2015 and fiscal year 2015 was $25.9 million and $33.5 million, respectively. Future annual amortization expense on intangible assets is estimated to be as follows:



Fiscal Year	Amount (in thousands)
2016	$	7,771
2017	$	32,195
2018	$	31,411
2019	$	29,666
2020 and thereafter	$	96,395

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

INVENTORIES

9 Months Ended

Dec. 26, 2015

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method.



(In thousands)	December 26, 2015		March 28, 2015
Raw materials	$	62,596	$	71,794
Work-in-process	16,421		12,462
Finished goods	124,846		126,821
Total inventory	$	203,863	$	211,077

DERIVATIVES AND FAIR VALUE MEASUREMENTS

9 Months Ended

Dec. 26, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVES AND FAIR VALUE MEASUREMENTS

We manufacture, market and sell our products globally. For the nine months ended December 26, 2015, approximately 43.1% of our sales were generated outside the U.S. in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, Australian Dollar, British Pound Sterling, Canadian Dollar and the Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of our designated foreign currency hedge contracts as of December 26, 2015 and March 28, 2015 were cash flow hedges under ASC Topic 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in Other Comprehensive (Loss) Income until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $112.9 million as of December 26, 2015 and $145.8 million as of March 28, 2015.

During the nine months ended December 26, 2015, we recognized net gains of $8.8 million in earnings from our cash flow hedges, compared to recognized net gains of $2.9 million during the nine months ended December 27, 2014. For the nine months ended December 26, 2015, a $1.1 million loss, net of tax, was recorded in Accumulated Other Comprehensive Loss to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to a gain of $8.4 million, net of tax, for the nine months ended December 27, 2014. At December 26, 2015, losses of $2.1 million, net of tax, will be reclassified to earnings within the next twelve months. All currency cash flow hedges outstanding as of December 26, 2015 mature within twelve months.

Non-Designated Foreign Currency Contracts

We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $48.6 million as of December 26, 2015 and $52.6 million as of March 28, 2015.

Interest Rate Swaps

On August 1, 2012, we entered into a credit agreement, as amended June 30, 2014, which provided for a term loan (“Credit Agreement”). Under the terms of this Credit Agreement, we may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, we have chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16th of 1% (“Adjusted LIBOR”). The terms of the Credit Agreement allows us to borrow in multiple tranches.

Accordingly, our earnings and cash flows are exposed to interest rate risk from changes in Adjusted LIBOR. Part of our interest rate risk management strategy includes the use of interest rate swaps to mitigate our exposure to changes in variable interest rates. Our objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. We formally document our hedge relationships (including identifying the hedged instrument and hedged item) at hedge inception to ensure that our interest rate swaps qualify for hedge accounting. On a quarterly basis, we assess whether the interest rate swaps are highly effective in offsetting changes in the cash flow of the hedged item. We do not hold or issue interest rate swaps for trading purposes. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote.

On December 21, 2012, we entered into two interest rate swap agreements (the "Swaps"), whereby we receive Adjusted LIBOR and pay an average fixed rate of 0.68% on a total notional amount of $250.0 million of debt. The Swaps mature on August 1, 2017. We designated the Swaps as cash flow hedges of variable interest rate risk associated with $250.0 million of indebtedness. For the nine months ended December 26, 2015 and December 27, 2014, a gain of $0.1 million and a loss of $0.3 million, respectively, net of tax, were recorded in Accumulated Other Comprehensive Loss to recognize the effective portion of the fair value of interest rate swaps that qualify as cash flow hedges.

Fair Value of Derivative Instruments

The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of income and comprehensive income for the nine months ended December 26, 2015:



(In thousands)	Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss			Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Earnings		Location in Consolidated Statements of Income and Comprehensive (Loss) Income	Amount of Gain Excluded from Effectiveness Testing *		Location in Consolidated Statements of Income and Comprehensive (Loss) Income
Derivative Instruments
Designated foreign currency hedge contracts, net of tax	$	(1,139	)	$	8,779	Net revenues, COGS, and SG&A	$	56	Interest and other expense, net
Non-designated foreign currency hedge contracts	—			—			972		Interest and other expense, net
Designated interest rate swaps, net of tax	$	139		$	—	Interest and other expense, net	$	—

* We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

We did not have fair value hedges or net investment hedges outstanding as of December 26, 2015 or March 28, 2015.

As of December 26, 2015, the amount recognized as a deferred tax liability for designated foreign currency hedges was $0.1 million.

ASC Topic 815 requires all derivative instruments to be recognized at their fair value as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of December 26, 2015, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of December 26, 2015 and March 28, 2015:



(In thousands)	Location in Balance Sheet	December 26, 2015		March 28, 2015
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	1,395	$	9,740
Designated interest rate swaps	Other current assets	65		—
		$	1,460	$	9,740
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	2,842	$	2,499
Designated interest rate swaps	Other current liabilities	—		159
		$	2,842	$	2,658

Other Fair Value Measurements

ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC Topic 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC Topic 820, for the nine months ended December 26, 2015, we applied the requirements under ASC Topic 820 to our non-financial assets and non-financial liabilities. As we did not have an impairment of any non-financial assets or non-financial liabilities, there was no disclosure required relating to our non-financial assets or non-financial liabilities.

On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency hedge contracts, and contingent consideration. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.

ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:


•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.


•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.


•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 26, 2015 and March 28, 2015.



	As of December 26, 2015								As of March 28, 2015
(In thousands)	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	66,712	$	—	$	—	$	66,712	$	119,946	$	—	$	—	$	119,946
Designated foreign currency hedge contracts	—		1,395		—		1,395		—		9,740		—		9,740
Designated interest rate swaps	—		65		—		65		—		—		—		—
	$	66,712	$	1,460	$	—	$	68,172	$	119,946	$	9,740	$	—	$	129,686
Liabilities
Designated foreign currency hedge contracts	$	—	$	2,842	$	—	$	2,842	$	—	$	2,499	$	—	$	2,499
Designated interest rate swaps	—		—		—		—		—		159		—		159
Contingent consideration	—		—		—		—		—		—		4,727		4,727
	$	—	$	2,842	$	—	$	2,842	$	—	$	2,658	$	4,727	$	7,385

For the nine months ended December 26, 2015, non-designated foreign currency hedge contracts were not significant and are not disclosed separately in the above table.

Contingent Consideration

Contingent consideration liabilities are measured at fair value using projected revenues, discount rates, probabilities of payment and projected payment dates. This Level 3 fair value measurement was performed using a probability-weighted discounted cash flow over a ten year period. Increases or decreases in the fair value of our contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing and amount of revenue estimates or likelihood of earning revenue. Projected revenues are based on our most recent internal operational budgets.

The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the nine months ended December 26, 2015.



(In thousands)	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Contingent consideration as of March 28, 2015	$	4,727
Fair value adjustment	171
Contingent consideration income	(4,898		)
Ending balance	$	—

As discussed in Note 6, Goodwill and Intangible Assets, during the nine months ended December 26, 2015, we reversed the remaining $4.9 million of contingent consideration liability associated with the SOLX asset, as we now do not expect to achieve the conditions that called for its payment. This reversal, as well as the fair value adjustment recorded, are included in the Consolidated Statements of (Loss) Income for the nine months ended December 26, 2015.

Other Fair Value Disclosures

The Term Loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value. Details pertaining to the Term Loan can be found in Note 10, Debt.

INCOME TAXES	9 Months Ended
INCOME TAXES	Dec. 26, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES We conduct business globally, and as a result, report our results of operations in a number of foreign jurisdictions in addition to the United States. Our reported tax rate is lower than the U.S. federal statutory rate in all reported periods as the income tax rates in the foreign jurisdictions are generally lower than the U.S. statutory tax rate. The reported income tax benefit rate for the nine months ended December 26, 2015 was 3.8%, as compared to a reported income tax provision rate of 7.8% for the nine months ended December 27, 2014. The change in our reported tax rate for the nine months ending December 26, 2015 relates primarily to the impact of impairment charges recorded during the third quarter of fiscal 2016. During the three and nine months ended December 26, 2015, we recorded goodwill impairment charges of $66.3 million and intangible asset impairment charges of $18.7 million with a corresponding $7.1 million benefit to income taxes. During the nine months ended December 26, 2015, we recorded pre-tax losses in Scotland, Italy and Malaysia due to restructuring and transformation costs associated with our manufacturing transformation, and we did not record a corresponding tax benefit due to the valuation allowance maintained against our net deferred tax assets in these jurisdictions. Similarly, during the nine months ended December 27, 2014, we recorded pre-tax losses in Scotland, Italy and Malaysia associated with restructuring costs, and we did not record a corresponding tax benefit due to uncertainty around our ability to realize a tax benefit in these jurisdictions. In addition, we recorded discrete tax benefits during the three months ended December 26, 2015 associated with the release of tax reserves due to the expiration of the statute of limitations as well as the retroactive enactment of the U.S. federal research credit. We recorded tax expense of $1.0 million during the nine months ended December 26, 2015 as a result of a deferred tax rate change which impacted an indefinite-lived deferred tax liability of our Puerto Rican subsidiary. We are in a three year cumulative loss position in the U.S. and, accordingly, maintain a valuation allowance against our U.S. deferred tax assets. We also maintain a valuation allowance against certain foreign deferred tax assets which we have concluded are not more-likely-than-not realizable.

DEBT

9 Months Ended

Dec. 26, 2015

Debt Disclosure [Abstract]

DEBT

On August 1, 2012, we entered into a credit agreement ("Credit Agreement") with certain lenders (together, “Lenders”) which provided for a $475.0 million Term Loan and a $50.0 million revolving loan (the “Revolving Credit Facility”), and together with the Term Loan, (the “Credit Facilities”). The Credit Facilities had a term of five years and mature on August 1, 2017. Interest was based on the Adjusted LIBOR plus a range of 1.125% to 1.500% depending on the achievement of leverage ratios and customary credit terms which included financial and negative covenants.

On June 30, 2014, we modified our existing Credit Facilities by extending the maturity date to July 1, 2019, extending the principal repayments of the Term Loan, and modifying certain restrictive covenants to allow greater operational flexibility and enhanced near term liquidity. In addition, the amended Credit Agreement provides for a $100.0 million revolving credit facility and establishes interest rates in the range of LIBOR plus 1.125% – 1.500%, depending on certain conditions. At December 26, 2015, $372.3 million was outstanding under the term loan and $50.0 million was outstanding on the Revolving Credit Facility, both with an interest rate of 1.625%. No additional amounts were borrowed as a result of this modification. The fair value of debt approximates its current value of approximately $422.3 million as of December 26, 2015. We were in compliance with the leverage and interest coverage ratios specified in the Credit Agreement as well as all other bank covenants as of December 26, 2015. The goodwill and intangible asset impairment charges discussed in Note 6, Goodwill and Intangible Assets, are excluded from the definition of consolidated EBITDA in the Credit Agreement.

The maturity profile is as follows:



Fiscal year (in thousands)	Term Loan
2016	$	14,228
2017	42,683
2018	45,054
2019	151,763
2020	168,564
	$	422,292

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 26, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES We are presently engaged in various legal actions, and although the total liability cannot be determined at the present time, based on consultation with counsel, we believe that any such liability will not materially affect our consolidated financial position or our results of operations. Italian Employment Litigation Our Italian manufacturing subsidiary is party to several actions initiated by employees of the facility in Ascoli-Piceno, Italy where we have ceased manufacturing operations. These include actions claiming (i) working conditions and minimum salaries should have been established by either a different classification under their national collective bargaining agreement or a different agreement altogether, (ii) certain solidarity agreements, which are arrangements between the Company, employees and the government to continue full pay and benefits for employees who would otherwise be terminated in times of low demand, are void, and (iii) payment of the extra time used for changing into and out of the working clothes at the beginning and end of each shift. In addition, a union represented in the Ascoli plant has filed an action claiming that the Company discriminated against it in favor of three other represented unions by (i) interfering with an employee referendum, (ii) interfering with an employee petition to recall union representatives from office, and (iii) excluding the union from certain meetings. Finally, we have been added as defendants on claims filed against Pall Corporation prior to our acquisition of the plant in August 2012. These claims relate to agreements to "freeze" benefit allowances for a certain period in exchange for Pall's commitments on hiring and plant investment. As of December 26, 2015, the total amount of damages claimed by the plaintiffs in these matters is approximately $3.7 million. It is not possible at this point in the proceedings to accurately evaluate the likelihood or amount of any potential losses and therefore no amounts have been accrued. We may receive other, similar claims in the future.

SEGMENT INFORMATION	9 Months Ended
SEGMENT INFORMATION	Dec. 26, 2015
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION We manage a global business which designs, manufactures and markets blood management solutions. Our solutions are marketed through operating segments organized primarily on geography: North America Plasma, Americas Blood Center and Hospital, Europe, Middle East, and Africa (collectively "EMEA"), Asia Pacific and Japan. ASC 280, Segment Reporting, permits the aggregation of segments which are economically similar as well as similar in all of the following areas: (i) the nature of the products and services, (ii) the nature of the production processes, (iii) the type or class of customer for their products and services, (iv) the methods used to distribute their products or provide their services, and (v) the nature of the regulatory environment. Based on the criteria of ASC 280, we have one reportable segment. This conclusion is consistent with how our chief operating decision-maker views the business. Our chief operating decision maker primarily uses consolidated results to make operating and strategic decisions.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

RESTRUCTURING

9 Months Ended

Dec. 26, 2015

Restructuring and Related Activities [Abstract]

RESTRUCTURING

On an ongoing basis, we review the global economy, the healthcare industry and the markets in which we compete to identify opportunities for efficiencies, enhance commercial capabilities, align our resources and offer our customers better solutions. In order to realize these opportunities, we undertake restructuring-type activities to transform our business.

On May 1, 2013, we committed to a plan to pursue identified Value Creation and Capture initiatives ("VCC"). These opportunities include investment in product line extensions and next generation products, enhancement of commercial capabilities and a transformation of our manufacturing network. The transformation of our manufacturing network is expected to be completed in fiscal 2017 and included changes to the manufacturing footprint and supply chain structure (the "Network Plan"). To date, we have (i) discontinued manufacturing activities at our Ascoli-Piceno, Italy and Braintree, Massachusetts facilities, (ii) expanded our facility in Tijuana, Mexico, (iii) engaged Sanmina Corporation as a contract manufacturer to produce certain medical equipment, and (iv) built a new manufacturing facility in Penang, Malaysia closer to our customers in Asia. We expect to complete the transfer of manufacturing activities from the Bothwell, Scotland facility by the middle of fiscal 2017. This transition will complete our VCC initiatives announced on May 1, 2013. See the Liquidity and Capital Resources discussion of the Management Discussion and Analysis of Financial Condition and Results of Operations for further discussion of the costs of these activities.

The following summarizes the restructuring costs for the nine months ended December 26, 2015 and December 27, 2014:



	Nine Months Ended December 26, 2015
(In thousands)	Restructuring Accrual Balance at March 28, 2015		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at December 26, 2015
Severance and other employee costs	$	16,393	$	9,141	$	(16,150	)	$	—		$	9,384
Other costs	219		7,846		(7,188		)	—			877
Accelerated depreciation	—		1,258		—			(1,258		)	—
Asset write-down	—		4		—			(4		)	—
Total	$	16,612	$	18,249	$	(23,338	)	$	(1,262	)	$	10,261



	Nine Months Ended December 27, 2014
(in thousands)	Restructuring Accrual Balance at March 29, 2014		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at December 27, 2014
Severance and other employee costs	$	22,908	$	15,633	$	(21,785	)	$	—		$	16,756
Other costs	728		12,044		(12,527		)	—			245
Accelerated depreciation	—		1,158		—			(1,158		)	—
Asset write-down	—		295		—			(295		)	—
	$	23,636	$	29,130	$	(34,312	)	$	(1,453	)	$	17,001

We deployed significant financial resources for these activities. Many of the costs necessary to complete the VCC initiatives, such as severance and other plant closing costs, qualify as restructuring expenses under ASC 420, Exit or Disposal Cost Obligations. We incurred $18.2 million in severance, asset write-downs and other restructuring charges during the nine months ended December 26, 2015. In addition, we also incurred $6.9 million of costs that do not constitute restructuring under ASC 420, which we refer to as "Transformation Costs". These costs consist primarily of expenditures directly related to our transformation activities including program management, product line transfer teams and related costs, infrastructure related costs, accelerated depreciation and asset disposals.

We estimate we will incur approximately $40 million in restructuring and transformation costs, net of contingent consideration income, in fiscal 2016. The table below presents transformation and restructuring costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and interest and other expense in our Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the periods presented.



Transformation costs	Three Months Ended					Nine Months Ended
(in thousands)	December 26, 2015			December 27, 2014		December 26, 2015		December 27, 2014
Transformation and other costs	$	(235	)	$	5,892	$	6,774	$	20,877
Accelerated depreciation	10			351		86		769
Asset disposal	18			471		18		471
Total	$	(207	)	$	6,714	$	6,878	$	22,117



Restructuring costs	Three Months Ended				Nine Months Ended
(in thousands)	December 26, 2015		December 27, 2014		December 26, 2015		December 27, 2014
Severance and other employee costs	$	1,181	$	2,887	$	9,141	$	15,633
Other costs	2,270		2,691		7,846		12,044
Accelerated depreciation	415		418		1,258		1,158
Asset disposal	—		199		4		295
Total	$	3,866	$	6,195	$	18,249	$	29,130

Total restructuring and transformation	$	3,659	$	12,909	$	25,127	$	51,247

As discussed in Note 8, Derivatives and Fair Value Measurements, during the three and nine months ended December 26, 2015, we reversed $4.9 million of contingent consideration associated with the SOLX asset, as we now do not expect to achieve the conditions that called for its payment. This reversal is reflected in transformation and other costs in the table above.

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	9 Months Ended
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	Dec. 26, 2015
Research and Development [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS For costs incurred related to the development of software to be sold, leased or otherwise marketed, we apply the provisions of ASC 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. We capitalized $12.9 million and $6.6 million in software development costs for ongoing initiatives during the nine months ended December 26, 2015 and December 27, 2014, respectively. At December 26, 2015 and March 28, 2015, we have a total of $52.6 million and $39.7 million of capitalized software costs, of which $14.3 million and $7.9 million are related to in-process software development initiatives, respectively. During the nine months ended December 26, 2015, $6.4 million of capitalized costs were placed into service. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. We review these assets for impairment at least annually.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

ACCUMULATED OTHER COMPREHENSIVE INCOME

9 Months Ended

Dec. 26, 2015

Stockholders' Equity Note [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME

ACCUMULATED OTHER COMPREHENSIVE LOSS

The following is a roll-forward of the components of Accumulated Other Comprehensive Loss, net of tax, for the nine months ended December 26, 2015:



(In thousands)	Foreign Currency			Defined Benefit Plans			Net Unrealized Gain/Loss on Derivatives			Total

Balance as of March 28, 2015	$	(20,512	)	$	(8,923	)	$	7,711		$	(21,724	)
Other comprehensive (loss)/income before reclassifications	(9,849		)	3			(1,000		)	(10,846		)
Amounts reclassified from Accumulated Other Comprehensive Loss	—			—			(8,779		)	(8,779		)
Net current period other comprehensive (loss)/income	(9,849		)	3			(9,779		)	(19,625		)
Balance as of December 26, 2015	$	(30,361	)	$	(8,920	)	$	(2,068	)	$	(41,349	)

Details pertaining to the amount reclassified from Accumulated Other Comprehensive Loss for the nine months ended December 26, 2015 are as follows:



	Amounts Reclassified from Other Comprehensive Loss			Affected Line in the Statement of Income
Derivative instruments reclassified to income statement
Realized net gain on derivatives	$	8,830		Net revenues, Cost of goods sold, Interest and other expense, net
Income tax effect	(51		)	Provision for (benefit from) income taxes
Net of taxes	$	8,779

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

BASIS OF PRESENTATION (Policies)	9 Months Ended
BASIS OF PRESENTATION (Policies)	Dec. 26, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue Recognition	Revenue Recognition We offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to estimate the expected rebates reasonably, we record a liability for the maximum potential rebate or discount that could be earned. In circumstances where we provide upfront rebate payments to customers, we capitalize the rebate payments and amortize the resulting asset as a reduction of revenue using a systematic method over the life of the contract. For additional information regarding significant accounting policies, refer to our annual report on Form 10-K for the fiscal year ended March 28, 2015.

EARNINGS PER SHARE ("EPS") (Tables)

9 Months Ended

Dec. 26, 2015

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.



	Three Months Ended
(In thousands, except per share amounts)	December 26, 2015			December 27, 2014
Basic EPS
Net (loss) income	$	(59,440	)	$	15,988
Weighted average shares	50,741			51,432
Basic (loss) income per share	$	(1.17	)	$	0.31
Diluted EPS
Net (loss) income	$	(59,440	)	$	15,988
Basic weighted average shares	50,741			51,432
Net effect of common stock equivalents	—			530
Diluted weighted average shares	50,741			51,962
Diluted (loss) income per share	$	(1.17	)	$	0.31



	Nine Months Ended
(In thousands, except per share amounts)	December 26, 2015			December 27, 2014
Basic EPS
Net (loss) income	$	(46,844	)	$	19,827
Weighted average shares	50,927			51,521
Basic (loss) income per share	$	(0.92	)	$	0.38
Diluted EPS
Net (loss) income	$	(46,844	)	$	19,827
Basic weighted average shares	50,927			51,521
Net effect of common stock equivalents	—			503
Diluted weighted average shares	50,927			52,024
Diluted (loss) income per share	$	(0.92	)	$	0.38

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Dec. 26, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Assumptions Utilized for Estimating Fair Value of Option Grants

The assumptions utilized for estimating the fair value of option grants during the periods presented are as follows:



	Nine Months Ended
	December 26, 2015		December 27, 2014
Stock Options Black-Scholes assumptions (weighted average):
Volatility	22.82	%	22.45	%
Expected life (years)	4.9		4.9
Risk-free interest rate	1.40	%	1.75	%
Dividend yield	—	%	—	%

PRODUCT WARRANTIES (Tables)

9 Months Ended

Dec. 26, 2015

Product Warranties Disclosures [Abstract]

Schedule of Product Warranty Liability

We estimate our potential warranty expense based on our historical warranty experience and periodically assess the adequacy of our warranty accrual, making adjustments as necessary.



	Nine Months Ended
(In thousands)	December 26, 2015			December 27, 2014
Warranty accrual as of the beginning of the period	$	531		$	590
Warranty provision	532			890
Warranty spending	(701		)	(941		)
Warranty accrual as of the end of the period	$	362		$	539

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Dec. 26, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill for fiscal 2016 and 2015 are as follows:



(In thousands)
Carrying amount as of March 29, 2014	$	336,768
Effects of change in foreign currency exchange rates	(2,458		)
Carrying amount as of March 28, 2015	$	334,310
Impairment charge	(66,305		)
Effects of change in foreign currency exchange rates	(1,060		)
Carrying amount as of December 26, 2015	$	266,945

Schedule of Amoritized Intangibles

The gross carrying amount of intangible assets and the related accumulated amortization, as of December 26, 2015 and March 28, 2015 is as follows:



(In thousands)	Gross Carrying Amount		Accumulated Amortization⁽¹⁾		Net		Weighted Average Useful Life
							(In years)
As of December 26, 2015
Patents	$	11,210	$	7,445	$	3,765	9
Capitalized software	52,557		9,242		43,315		6
Other developed technology	126,066		70,887		55,179		12
Customer contracts and related relationships	195,368		84,758		110,610		10
Trade names	7,032		5,092		1,940		11
Total intangibles	$	392,233	$	177,424	$	214,809	10

⁽¹⁾Includes impairment of SOLX asset, as discussed above.



(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net		Weighted Average Useful Life
							(In years)
As of March 28, 2015
Patents	$	10,473	$	7,373	$	3,100	9
Capitalized software	39,690		5,654		34,036		7
Other developed technology	124,573		46,474		78,099		12
Customer contracts and related relationships	195,985		70,440		125,545		10
Trade names	7,042		3,234		3,808		11
Total intangibles	$	377,763	$	133,175	$	244,588	10

Schedule of Future Amortization Expense

Future annual amortization expense on intangible assets is estimated to be as follows:



Fiscal Year	Amount (in thousands)
2016	$	7,771
2017	$	32,195
2018	$	31,411
2019	$	29,666
2020 and thereafter	$	96,395

INVENTORIES (Tables)

9 Months Ended

Dec. 26, 2015

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method.



(In thousands)	December 26, 2015		March 28, 2015
Raw materials	$	62,596	$	71,794
Work-in-process	16,421		12,462
Finished goods	124,846		126,821
Total inventory	$	203,863	$	211,077

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Dec. 26, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments



(In thousands)	Amount of Gain (Loss) Recognized in Accumulated Other Comprehensive Loss			Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Earnings		Location in Consolidated Statements of Income and Comprehensive (Loss) Income	Amount of Gain Excluded from Effectiveness Testing *		Location in Consolidated Statements of Income and Comprehensive (Loss) Income
Derivative Instruments
Designated foreign currency hedge contracts, net of tax	$	(1,139	)	$	8,779	Net revenues, COGS, and SG&A	$	56	Interest and other expense, net
Non-designated foreign currency hedge contracts	—			—			972		Interest and other expense, net
Designated interest rate swaps, net of tax	$	139		$	—	Interest and other expense, net	$	—

* We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of December 26, 2015 and March 28, 2015:



(In thousands)	Location in Balance Sheet	December 26, 2015		March 28, 2015
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	1,395	$	9,740
Designated interest rate swaps	Other current assets	65		—
		$	1,460	$	9,740
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	2,842	$	2,499
Designated interest rate swaps	Other current liabilities	—		159
		$	2,842	$	2,658

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 26, 2015 and March 28, 2015.



	As of December 26, 2015								As of March 28, 2015
(In thousands)	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	66,712	$	—	$	—	$	66,712	$	119,946	$	—	$	—	$	119,946
Designated foreign currency hedge contracts	—		1,395		—		1,395		—		9,740		—		9,740
Designated interest rate swaps	—		65		—		65		—		—		—		—
	$	66,712	$	1,460	$	—	$	68,172	$	119,946	$	9,740	$	—	$	129,686
Liabilities
Designated foreign currency hedge contracts	$	—	$	2,842	$	—	$	2,842	$	—	$	2,499	$	—	$	2,499
Designated interest rate swaps	—		—		—		—		—		159		—		159
Contingent consideration	—		—		—		—		—		—		4,727		4,727
	$	—	$	2,842	$	—	$	2,842	$	—	$	2,658	$	4,727	$	7,385

Schedule of Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the nine months ended December 26, 2015.



(In thousands)	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Contingent consideration as of March 28, 2015	$	4,727
Fair value adjustment	171
Contingent consideration income	(4,898		)
Ending balance	$	—

DEBT (Tables)

9 Months Ended

Dec. 26, 2015

Debt Disclosure [Abstract]

Schedule of Maturities of Long-term Debt

The maturity profile is as follows:



Fiscal year (in thousands)	Term Loan
2016	$	14,228
2017	42,683
2018	45,054
2019	151,763
2020	168,564
	$	422,292

RESTRUCTURING (Tables)

9 Months Ended

Dec. 26, 2015

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost

The following summarizes the restructuring costs for the nine months ended December 26, 2015 and December 27, 2014:



	Nine Months Ended December 26, 2015
(In thousands)	Restructuring Accrual Balance at March 28, 2015		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at December 26, 2015
Severance and other employee costs	$	16,393	$	9,141	$	(16,150	)	$	—		$	9,384
Other costs	219		7,846		(7,188		)	—			877
Accelerated depreciation	—		1,258		—			(1,258		)	—
Asset write-down	—		4		—			(4		)	—
Total	$	16,612	$	18,249	$	(23,338	)	$	(1,262	)	$	10,261



	Nine Months Ended December 27, 2014
(in thousands)	Restructuring Accrual Balance at March 29, 2014		Restructuring Costs Incurred		Less Payments			Less Non-Cash Adjustments			Restructuring Accrual Balance at December 27, 2014
Severance and other employee costs	$	22,908	$	15,633	$	(21,785	)	$	—		$	16,756
Other costs	728		12,044		(12,527		)	—			245
Accelerated depreciation	—		1,158		—			(1,158		)	—
Asset write-down	—		295		—			(295		)	—
	$	23,636	$	29,130	$	(34,312	)	$	(1,453	)	$	17,001

Schedule of Restructuring and Related Costs

The table below presents transformation and restructuring costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and interest and other expense in our Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the periods presented.



Transformation costs	Three Months Ended					Nine Months Ended
(in thousands)	December 26, 2015			December 27, 2014		December 26, 2015		December 27, 2014
Transformation and other costs	$	(235	)	$	5,892	$	6,774	$	20,877
Accelerated depreciation	10			351		86		769
Asset disposal	18			471		18		471
Total	$	(207	)	$	6,714	$	6,878	$	22,117



Restructuring costs	Three Months Ended				Nine Months Ended
(in thousands)	December 26, 2015		December 27, 2014		December 26, 2015		December 27, 2014
Severance and other employee costs	$	1,181	$	2,887	$	9,141	$	15,633
Other costs	2,270		2,691		7,846		12,044
Accelerated depreciation	415		418		1,258		1,158
Asset disposal	—		199		4		295
Total	$	3,866	$	6,195	$	18,249	$	29,130

Total restructuring and transformation	$	3,659	$	12,909	$	25,127	$	51,247

COMPREHENSIVE INCOME (Tables)

9 Months Ended

Dec. 26, 2015

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following is a roll-forward of the components of Accumulated Other Comprehensive Loss, net of tax, for the nine months ended December 26, 2015:



(In thousands)	Foreign Currency			Defined Benefit Plans			Net Unrealized Gain/Loss on Derivatives			Total

Balance as of March 28, 2015	$	(20,512	)	$	(8,923	)	$	7,711		$	(21,724	)
Other comprehensive (loss)/income before reclassifications	(9,849		)	3			(1,000		)	(10,846		)
Amounts reclassified from Accumulated Other Comprehensive Loss	—			—			(8,779		)	(8,779		)
Net current period other comprehensive (loss)/income	(9,849		)	3			(9,779		)	(19,625		)
Balance as of December 26, 2015	$	(30,361	)	$	(8,920	)	$	(2,068	)	$	(41,349	)

Reclassification out of Accumulated Other Comprehensive Income

Details pertaining to the amount reclassified from Accumulated Other Comprehensive Loss for the nine months ended December 26, 2015 are as follows:



	Amounts Reclassified from Other Comprehensive Loss			Affected Line in the Statement of Income
Derivative instruments reclassified to income statement
Realized net gain on derivatives	$	8,830		Net revenues, Cost of goods sold, Interest and other expense, net
Income tax effect	(51		)	Provision for (benefit from) income taxes
Net of taxes	$	8,779

BASIS OF PRESENTATION (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Dec. 26, 2015	Mar. 28, 2015
Basis of Presentation [Line Items]
Correction of understatement, provision for income taxes	$ 1.0
Term of fiscal years	371 days	364 days
Term of quarters		91 days
First Three Quarters [Member]
Basis of Presentation [Line Items]
Term of quarters	91 days
Fourth Quarter [Member]
Basis of Presentation [Line Items]
Term of quarters	98 days
Operating Income (Loss) [Member]
Basis of Presentation [Line Items]
Correction of understatement, provision for income taxes	$ 1.1

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Dec. 26, 2015	Dec. 27, 2014
Basic EPS
Net (loss) income	$ (59,440)	$ 15,988	$ (46,844)	$ 19,827
Basic weighted average shares (in shares)	50,741	51,432	50,927	51,521
Basic income (loss) per share (in dollars per share)	$ (1.17)	$ 0.31	$ (0.92)	$ 0.38
Diluted EPS
Net (loss) income	$ (59,440)	$ 15,988	$ (46,844)	$ 19,827
Basic weighted average shares (in shares)	50,741	51,432	50,927	51,521
Net effect of common stock equivalents (in shares)	0	530	0	503
Diluted weighted average shares (in shares)	50,741	51,962	50,927	52,024
Diluted income (loss) per share (in dollars per share)	$ (1.17)	$ 0.31	$ (0.92)	$ 0.38
Stock awards excluded from computation of weighted average shares outstanding (in shares)		1,700		1,600

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

STOCK-BASED COMPENSATION (Details) - USD ($)	9 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($)	Dec. 26, 2015	Dec. 27, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation expense recognized	$ 6,199,000	$ 10,219,000
Tax benefit from compensation expense	$ 0	$ 3,300,000
Weighted average fair value of options granted (in dollars per share)	$ 7.41	$ 7.89
Stock Options Black-Scholes assumptions (weighted average):
Volatility	22.82%	22.45%
Expected life (years)	4 years 10 months 24 days	4 years 10 months 24 days
Risk-free interest rate	1.40%	1.75%
Dividend yield	0.00%	0.00%
Total unrecognized compensation cost	$ 18,200,000
Total unrecognized compensation cost related to non-vested stock options, weighted average period of recognition	2 years 10 months 24 days
Shares purchased under the ESPP (in shares)	145,334	183,808
Shares purchased under the ESPP (in dollars per share)	$ 29.87	$ 25.92

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the period	$ 531	$ 590
Warranty provision	532	890
Warranty spending	(701)	(941)
Warranty accrual as of the end of the period	$ 362	$ 539

GOODWILL AND INTANGIBLE ASSETS Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 26, 2015	Dec. 26, 2015	Mar. 28, 2015
Goodwill [Roll Forward]
Goodwill, carrying amount		$ 334,310	$ 336,768
Impairment charge	$ (66,305)	(66,305)
Effects of change in foreign currency exchange rates		(1,060)	(2,458)
Goodwill, carrying amount	$ 266,945	$ 266,945	$ 334,310
Americas Blood Center and Hospital
Goodwill [Line Items]
Reporting unit, excess fair value over carrying value	25.80%	25.80%
Goodwill [Roll Forward]
Goodwill, carrying amount	$ 175,900	$ 175,900

GOODWILL AND INTANGIBLE ASSETS Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Dec. 26, 2015	Dec. 27, 2014	Mar. 28, 2015
Finite-Lived Intangible Assets [Line Items]
Impairment charge	$ 18,700		$ 18,700
Contingent consideration (income) expense	(4,898)	$ 246	(4,727)	$ 706
Intangible Assets
Gross Carrying Amount	392,233		392,233		$ 377,763
Accumulated Amortization	177,424		177,424		133,175
Net	214,809		$ 214,809		$ 244,588
Weighted average useful life			10 years		10 years
Aggregate amortization expense			$ 25,900		$ 33,500
Future amortization expense, year one	7,771		7,771
Future amortization expense, year two	32,195		32,195
Future amortization expense, year three	31,411		31,411
Future amortization expense, year four	29,666		29,666
Future amortization expense, year five and thereafter	96,395		96,395
Patents
Intangible Assets
Gross Carrying Amount	11,210		11,210		10,473
Accumulated Amortization	7,445		7,445		7,373
Net	3,765		$ 3,765		$ 3,100
Weighted average useful life			9 years		9 years
Capitalized software
Intangible Assets
Gross Carrying Amount	52,557		$ 52,557		$ 39,690
Accumulated Amortization	9,242		9,242		5,654
Net	43,315		$ 43,315		$ 34,036
Weighted average useful life			6 years		7 years
Other developed technology
Intangible Assets
Gross Carrying Amount	126,066		$ 126,066		$ 124,573
Accumulated Amortization	70,887		70,887		46,474
Net	55,179		$ 55,179		$ 78,099
Weighted average useful life			12 years		12 years
Customer contracts and related relationships
Intangible Assets
Gross Carrying Amount	195,368		$ 195,368		$ 195,985
Accumulated Amortization	84,758		84,758		70,440
Net	110,610		$ 110,610		$ 125,545
Weighted average useful life			10 years		10 years
Trade names
Intangible Assets
Gross Carrying Amount	7,032		$ 7,032		$ 7,042
Accumulated Amortization	5,092		5,092		3,234
Net	$ 1,940		$ 1,940		$ 3,808
Weighted average useful life			11 years		11 years
Minimum
Intangible Assets
Weighted average useful life					2 years
Maximum
Intangible Assets
Weighted average useful life					19 years
Hemerus Medical, LLC [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment charge			$ 18,700
Contingent consideration (income) expense			$ 4,900

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Dec. 26, 2015	Mar. 28, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 62,596	$ 71,794
Work-in-process	16,421	12,462
Finished goods	124,846	126,821
Inventories, net	$ 203,863	$ 211,077

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ (1,139)	$ 8,400
Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Exchange Contract \| Net revenues, COGS, and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	8,779	2,900
Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Exchange Contract \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	56
Designated as Hedging Instrument \| Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	139	$ (300)
Amount Excluded from Effectiveness Testing	0
Designated as Hedging Instrument \| Interest Rate Swap [Member] \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	0
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument \| Foreign Exchange Contract \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	$ 972

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	Dec. 26, 2015	Mar. 28, 2015
Derivative Assets:
Derivative Assets	$ 1,460	$ 9,740
Derivative Liabilities:
Derivative Liabilities	2,842	2,658
Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Assets
Derivative Assets:
Derivative Assets	1,395	9,740
Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	2,842	2,499
Designated as Hedging Instrument \| Interest Rate Swap [Member] \| Other Current Assets
Derivative Assets:
Derivative Assets	65	0
Designated as Hedging Instrument \| Interest Rate Swap [Member] \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	$ 0	$ 159

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Dec. 26, 2015	Dec. 27, 2014	Mar. 28, 2015
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Contingent consideration income	$ 4,898	$ (246)	$ 4,727	$ (706)
Quoted Market Prices for Identical Assets (Level 1)
Assets
Designated interest rate swaps	0		0
Fair Value, Inputs, Level 3 [Member]
Assets
Designated interest rate swaps	0		0
Fair Value, Measurements, Recurring [Member]
Assets
Money market funds	66,712		66,712		$ 119,946
Designated foreign currency hedge contracts	1,395		1,395		9,740
Designated interest rate swaps	65		65		0
Assets, Fair Value Disclosure, Total	68,172		68,172		129,686
Liabilities
Designated foreign currency hedge contracts	2,842		2,842		2,499
Designated interest rate swap	0		0		159
Contingent consideration liability	0		0		4,727
Liabilities, Fair Value Disclosure	2,842		2,842		7,385
Fair Value, Measurements, Recurring [Member] \| Quoted Market Prices for Identical Assets (Level 1)
Assets
Money market funds	66,712		66,712		119,946
Designated foreign currency hedge contracts	0		0		0
Designated interest rate swaps					0
Assets, Fair Value Disclosure, Total	66,712		66,712		119,946
Liabilities
Designated foreign currency hedge contracts	0		0		0
Designated interest rate swap	0		0		0
Contingent consideration liability	0		0		0
Liabilities, Fair Value Disclosure	0		0		0
Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2)
Assets
Money market funds	0		0		0
Designated foreign currency hedge contracts	1,395		1,395		9,740
Designated interest rate swaps	65		65		0
Assets, Fair Value Disclosure, Total	1,460		1,460		9,740
Liabilities
Designated foreign currency hedge contracts	2,842		2,842		2,499
Designated interest rate swap	0		0		159
Contingent consideration liability	0		0		0
Liabilities, Fair Value Disclosure	2,842		2,842		2,658
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets
Money market funds	0		0		0
Designated foreign currency hedge contracts	0		0		0
Designated interest rate swaps					0
Assets, Fair Value Disclosure, Total	0		0		0
Liabilities
Designated foreign currency hedge contracts	0		0		0
Designated interest rate swap	0		0		0
Contingent consideration liability	0		0		4,727
Liabilities, Fair Value Disclosure	$ 0		0		$ 4,727
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Contingent consideration as of March 28, 2015			4,727
Fair value adjustment			171
Contingent consideration income			$ (4,898)

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) $ in Thousands		3 Months Ended		9 Months Ended
	Dec. 21, 2012 USD ($) swap	Dec. 26, 2015 USD ($)	Dec. 27, 2014 USD ($)	Dec. 26, 2015 USD ($)	Dec. 27, 2014 USD ($)	Mar. 28, 2015 USD ($)
Derivative [Line Items]
Percentage of sales generated outside the US				43.10%
Maturity period for foreign currency contracts (in years)				1 year
Designated foreign currency hedge contracts outstanding		$ 112,900		$ 112,900		$ 145,800
Non-designated foreign currency hedge contracts outstanding		48,600		48,600		52,600
Deferred income tax expense (benefit)		(7,088)		(7,088)	$ 0
Contingent consideration income		$ 4,898	$ (246)	$ 4,727	(706)
Foreign Exchange Contract
Derivative [Line Items]
Maturity period for foreign currency contracts (in years)				1 year
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Deferred income tax expense (benefit)				$ 100
Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)				1,139	(8,400)
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months				2,100
Designated as Hedging Instrument \| Interest Rate Swap [Member]
Derivative [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)				(139)	300
Number of Interest Rate Derivatives Held \| swap	2
Description of variable rate basis	LIBOR
Derivative, fixed interest rate	0.68%
Notional amount of derivative	$ 250,000
Net revenues, COGS, and SG&A \| Designated as Hedging Instrument \| Cash Flow Hedging \| Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)				8,779	$ 2,900
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Derivative [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value						$ 4,727
Contingent consideration income				$ (4,898)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Dec. 26, 2015	Dec. 26, 2015	Dec. 27, 2014
Income Tax Disclosure [Abstract]
Reported tax rate		(3.80%)	7.80%
Goodwill impairment charge	$ 66,305	$ 66,305
Intangible asset impairment charge	18,700	18,700
Deferred tax benefit	$ 7,088	7,088	$ 0
Recorded tax expense due to tax rate increase in Puerto Rico		$ 1,000

DEBT (Details) $ in Thousands	9 Months Ended
DEBT (Details) $ in Thousands	Dec. 26, 2015 USD ($)
Debt Instrument [Line Items]
Debt outstanding	$ 422,292
2015	14,228
2016	42,683
2017	45,054
2018	151,763
2019 and beyond	$ 168,564
Credit Agreement [Member]
Debt Instrument [Line Items]
Term of credit facilities	5 years
Debt outstanding	$ 422,300
Credit Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Effective interest rate	1.625%
Credit Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Minimum
Debt Instrument [Line Items]
Interest Rate	1.125%
Credit Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Maximum
Debt Instrument [Line Items]
Interest Rate	1.50%
Term Loan [Member]
Debt Instrument [Line Items]
Face amount of debt	$ 475,000
Debt outstanding	372,300
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Face amount of debt	50,000
Debt outstanding	50,000
Maximum borrowing capacity	$ 100,000

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 26, 2015 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Damages claimed	$ 3,700,000
Amount accrued	$ 0

SEGMENT INFORMATION (Details)	9 Months Ended
SEGMENT INFORMATION (Details)	Dec. 26, 2015 segment
Segment Reporting [Abstract]
Number of reportable segments	1

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Dec. 26, 2015	Dec. 27, 2014
Restructuring Cost and Reserve [Line Items]
Contingent consideration (income) expense	$ (4,898)	$ 246	$ (4,727)	$ 706
Expected cost	40,000		40,000
Restructuring Costs Incurred	3,866	6,195	18,249	29,130
Transformation costs	$ (207)	$ 6,714	6,878	$ 22,117
Hemerus Medical, LLC [Member]
Restructuring Cost and Reserve [Line Items]
Contingent consideration (income) expense			$ 4,900

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Dec. 26, 2015	Dec. 27, 2014
Restructuring Reserve [Roll Forward]
Restructuring Accrual Balance			$ 16,612	$ 23,636
Restructuring Costs Incurred	$ 3,866	$ 6,195	18,249	29,130
Less Payments			(23,338)	(34,312)
Less Non-Cash Adjustments			1,262	1,453
Restructuring Accrual Balance	10,261	17,001	10,261	17,001
Severance and other employee costs
Restructuring Reserve [Roll Forward]
Restructuring Accrual Balance			16,393	22,908
Restructuring Costs Incurred	1,181	2,887	9,141	15,633
Less Payments			(16,150)	(21,785)
Less Non-Cash Adjustments			0	0
Restructuring Accrual Balance	9,384	16,756	9,384	16,756
Other costs
Restructuring Reserve [Roll Forward]
Restructuring Accrual Balance			219	728
Restructuring Costs Incurred	2,270	2,691	7,846	12,044
Less Payments			(7,188)	(12,527)
Less Non-Cash Adjustments			0	0
Restructuring Accrual Balance	877	245	877	245
Accelerated depreciation
Restructuring Reserve [Roll Forward]
Restructuring Accrual Balance			0	0
Restructuring Costs Incurred	415	418	1,258	1,158
Less Payments			0	0
Less Non-Cash Adjustments			(1,258)	(1,158)
Restructuring Accrual Balance	0	0	0	0
Asset write-down
Restructuring Reserve [Roll Forward]
Restructuring Accrual Balance			0	0
Restructuring Costs Incurred			4	295
Less Payments			0	0
Less Non-Cash Adjustments			(4)	(295)
Restructuring Accrual Balance	$ 0	$ 0	$ 0	$ 0

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Dec. 26, 2015	Dec. 27, 2014
Restructuring Cost and Reserve [Line Items]
Transformation costs	$ (207)	$ 6,714	$ 6,878	$ 22,117
Restructuring Costs Incurred	3,866	6,195	18,249	29,130
Total restructuring and transformation	3,659	12,909	25,127	51,247
Severance and other employee costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	1,181	2,887	9,141	15,633
Other costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	2,270	2,691	7,846	12,044
Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	415	418	1,258	1,158
Asset disposal
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	0	199	4	295
Transformation and other costs
Restructuring Cost and Reserve [Line Items]
Transformation costs	(235)	5,892	6,774	20,877
Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Transformation costs	10	351	86	769
Asset disposal
Restructuring Cost and Reserve [Line Items]
Transformation costs	$ 18	$ 471	$ 18	$ 471

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Mar. 28, 2015
Research and Development [Abstract]
Capitalized software development costs for ongoing initiatives	$ 12.9	$ 6.6
Software costs capitalized, net	52.6		$ 39.7
Total costs capitalized related to in process software development initiatives	14.3		$ 7.9
Capitalized software development costs placed into service	$ 6.4

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 1) $ in Thousands	9 Months Ended
	Dec. 26, 2015 USD ($)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of March 28, 2015	$ (21,724)
Other comprehensive (loss)/income before reclassifications	(10,846)
Amounts reclassified from Accumulated Other Comprehensive Loss	(8,779)
Net current period other comprehensive (loss)/income	(19,625)
Balance as of December 26, 2015	(41,349)
Foreign Currency
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of March 28, 2015	(20,512)
Other comprehensive (loss)/income before reclassifications	(9,849)
Amounts reclassified from Accumulated Other Comprehensive Loss	0
Net current period other comprehensive (loss)/income	(9,849)
Balance as of December 26, 2015	(30,361)
Defined Benefit Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of March 28, 2015	(8,923)
Other comprehensive (loss)/income before reclassifications	3
Amounts reclassified from Accumulated Other Comprehensive Loss	0
Net current period other comprehensive (loss)/income	3
Balance as of December 26, 2015	(8,920)
Net Unrealized Gain/Loss on Derivatives
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of March 28, 2015	7,711
Other comprehensive (loss)/income before reclassifications	(1,000)
Amounts reclassified from Accumulated Other Comprehensive Loss	(8,779)
Net current period other comprehensive (loss)/income	(9,779)
Balance as of December 26, 2015	$ (2,068)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Dec. 26, 2015	Dec. 27, 2014
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives	$ (2,141)	$ (2,308)	$ (6,756)	$ (7,496)
Income tax effect	3,878	36	(1,696)	(1,679)
Net (loss) income	$ (59,440)	$ 15,988	(46,844)	$ 19,827
Net Unrealized Gain/Loss on Derivatives \| Amounts Reclassified from Other Comprehensive Loss
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives			8,830
Income tax effect			(51)
Net (loss) income			$ 8,779

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details